KALA BIO, INC. Liabilities Assumed
KALA BIO, INC. (KALA) reported Liabilities Assumed of $409.00 thousand for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:LiabilitiesAssumed1 · last filed 2019-11-07
- KALA BIO, INC. liabilities assumed for the quarter ending 2019-03-31 was $409.00K.
- KALA BIO, INC. liabilities assumed for the quarter ending 2018-12-31 was $45.00K.
- KALA BIO, INC. liabilities assumed for the quarter ending 2018-09-30 was $15.00K.
- KALA BIO, INC. liabilities assumed for fiscal 2018 was $155.00K.
| Period end | Liabilities Assumed 3 month | Liabilities Assumed 6 month | Liabilities Assumed 9 month | Liabilities Assumed 12 month |
|---|---|---|---|---|
| 2019-03-31 | $409.00K 10-Q · filed 2019-05-09 | $454.00K derived: sum of 2 quarters · filed 2019-05-09 | $469.00K derived: sum of 3 quarters · filed 2019-11-07 | |
| 2018-12-31 | $45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $60.00K derived: sum of 2 quarters · filed 2019-11-07 | $155.00K 10-K · filed 2019-03-12 | |
| 2018-09-30 | $15.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $110.00K 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $95.00K 10-Q · filed 2019-08-06 | |||
| 2017-09-30 | $45.00K 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |